Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 304-313

  Myint, Aye Mu ^a,c   Kim, Yong Ku ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Korea University   (South Korea)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Bipolar; Depression; Glutamate; IDO; Kynurenine; Schizophrenia

Indexed keywords

3 HYDROXYKYNURENINE; 4 AMINOBUTYRIC ACID; CYTOKINE; GLUTAMIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; NORADRENALIN; QUINOLINIC ACID; SEROTONIN; TRYPTOPHAN;

ARTICLE; BIPOLAR DISORDER; CHILDHOOD DISEASE; CHILDHOOD PSYCHIATRIC DISORDER; DEPRESSION; DISEASE MARKER; DOPAMINERGIC TRANSMISSION; GABAERGIC TRANSMISSION; GLIA CELL; GLUTAMATERGIC TRANSMISSION; HUMAN; IMMUNE SYSTEM; MENTAL DISEASE; METABOLITE; NERVE CELL; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC TRANSMISSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SCHIZOPHRENIA; TRYPTOPHAN METABOLISM;

3-HYDROXY-ANTHRANILLIC ACID OXIDASE; 3-HYDROXY-KYNURENINE; 3-HYDROXYANTHRANILIC ACID; 3HK; 5-HYDROXY INDOLE; 5-HYDROXYINDOLE ACETIC ACID; 5HI; 5HIAA; A7-NICOTINIC ACETYLCHOLINE RECEPTOR; A7NACHR; ACC; ACETYLCHOLINE; ACH; ADENOSINE TRIPHOSPHATE; ADHD; AFMK; AMCC; ANTERIOR CINGULATE CORTEX; ANTERIOR MID CINGULATE CORTEX; ATP; ATTENTION DEFICIT HYPERACTIVE DISORDER; BACILLE CALMETTE-GUÉRIN; BBB; BCG; BIPOLAR; BLOOD-BRAIN-BARRIER; CEREBROSPINAL FLUID; CSF; DA; DEPRESSION; DOPAMINE; F5OHKYM; FORMYL-5-HYDROXYKYNURAMINE; GABA; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE; HAA; HAAO; HEMEOXYGENASE 1; HO1; HPA; HYPOTHALAMO-PITUITARY-ADRENAL; IDO; IFN; IL1; INDOLEAMINE 2,3-DIOXYGENASE; INTERFERON; INTERLEUKIN; KATS; KMO; KYN; KYNA; KYNURENIC ACID; KYNURENINE; KYNURENINE AMINOTRANSFERASES; KYNURENINE-3-MONOOXYGENASE; MAGNETIC RESONANCE; MAO; MONOAMINE OXIDASE; MR; N-ACETYL-N-FORMYL-5METHOYKYNURAMINE; N-METHYL-D-ASPARTATE; NA; NAD; NICOTINAMIDE ADENINE DINUCLEOTIDE; NMDA; NMDA RECEPTOR; NMDA-R; NORADRENALINE; PGE2; PIC; PICOLINIC ACID; PROSTAGLANDIN E2; QUIN; QUINOLINIC ACID; SCHIZOPHRENIA; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SSRI; T HELPER; TDO; TH; TRP; TRYPTOPHAN; TRYPTOPHAN 2,3-DIOXYGENASE;

BRAIN; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MENTAL DISORDERS;

EID: 84889095470     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.08.008     Document Type: Article

References (137)

1. Ader R., Cohen N. Behaviorally conditioned immunosuppression. Psychosom Med 1975, 37(4):333-340.
2. Andreasen N.C., Rezai K., Alliger R., Swayze V.W., Flaum M., Kirchner P., et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992, 49(12):943-958.
3. Auer D.P., Putz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000, 47(4):305-313.
4. Balla A., Nattini M.E., Sershen H., Lajtha A., Dunlop D.S., Javitt D.C. GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum. Neuropharmacology 2009, 56(5):915-921.
5. Banerjee J., Alkondon M., Pereira E.F., Albuquerque E.X. Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. J Pharmacol Exp Ther 2012, 341(2):500-509.
6. Bender D.A. Effects of a dietary excess of leucine and of the addition of leucine and 2-oxo-isocaproate on the metabolism of tryptophan and niacin in isolated rat liver cells. Br J Nutr 1989, 61(3):629-640.
7. Bender D.A., McCreanor G.M. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans 1985, 13(2):441-443.
8. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47(4):351-354.
9. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002, 7(5):468-473.
10. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003, 54(9):906-914.
11. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 1987, 139(7):2414-2418.
12. Ceresoli-Borroni G., Rassoulpour A., Wu H.Q., Guidetti P., Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 2006, 113(10):1355-1365.
13. Chalifoux J.R., Carter A.G. GABAB receptor modulation of synaptic function. Curr Opin Neurobiol 2011, 21(2):339-344.
14. Chiarugi A., Calvani M., Meli E., Traggiai E., Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J Neuroimmunol 2001, 120(1-2):190-198.
15. Chisari M., Zorumski C.F., Mennerick S. Cross talk between synaptic receptors mediates NMDA-induced suppression of inhibition. J Neurophysiol 2012, 107(9):2532-2540.
16. Choi B.D., Fecci P.E., Sampson J.H. Regulatory T cells move in when gliomas say "I Do". Clin Cancer Res 2012, 18(22):6086-6088.
17. Claes S., Myint A.M., Domschke K., Del-Favero J., Entrich K., Engelborghs S., et al. The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res 2011, 188(3):355-360.
18. Condray R., Dougherty G.G., Keshavan M.S., Reddy R.D., Haas G.L., Montrose D.M., et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011, 1-12.
19. de Almeida E.A., Martinez G.R., Klitzke C.F., de Medeiros M.H., Di Mascio P. Oxidation of melatonin by singlet molecular oxygen (O2(1deltag)) produces N1-acetyl-N2-formyl-5-methoxykynurenine. J Pineal Res 2003, 35(2):131-137.
20. Donald E.A., Bosse T.R. The vitamin B6 requirement in oral contraceptive users. II. Assessment by tryptophan metabolites, vitamin B6, and pyridoxic acid levels in urine. Am J Clin Nutr 1979, 32(5):1024-1032.
21. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009, 50(11):1801-1807.
22. Erhardt S., Blennow K., Nordin C., Skogh E., Lindstrom L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001, 313(1-2):96-98.
23. Erhardt S., Schwieler L., Engberg G. Kynurenic acid and schizophrenia. Adv Exp Med Biol 2003, 527:155-165.
24. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23(2):91-101.
25. Eynard N., Flachaire E., Lestra C., Broyer M., Zaidan R., Claustrat B., et al. Platelet serotonin content and free and total plasma tryptophan in healthy volunteers during 24hours. Clin Chem 1993, 39(11 Pt 1):2337-2340.
26. Fernstrom J.D. Effects on the diet on brain neurotransmitters. Metabolism 1977, 26(2):207-223.
27. Fischer D.S. Toxic psychosis without fever as sign of acute meningitis. Arch Intern Med 1963, 111:54-57.
28. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002, 196(4):459-468.
29. Gabbay V., Klein R.G., Katz Y., Mendoza S., Guttman L.E., Alonso C.M., et al. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 2010, 51(8):935-943.
30. Gal E.M., Sherman A.D. L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 1980, 5(3):223-239.
31. Grant R.S., Kapoor V. Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 1998, 70(4):1759-1763.
32. Grant R.S., Naif H., Espinosa M., Kapoor V. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep 2000, 5(2-3):101-104.
33. Grilli M., Raiteri L., Patti L., Parodi M., Robino F., Raiteri M., et al. Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br J Pharmacol 2006, 149(6):724-732.
34. Gu H., Hu D., Hong X.R., Mao J., Cui Y., Hui N., et al. Changes and significance of orphanin and serotonin in patients with postpartum depression. Zhonghua Fu Chan Ke Za Zhi 2003, 38(12):727-728.
35. Guillemin G.J., Smith D.G., Kerr S.J., Smythe G.A., Kapoor V., Armati P.J., et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep 2000, 5(2-3):108-111.
36. Guillemin G.J., Kerr S.J., Smythe G.A., Smith D.G., Kapoor V., Armati P.J., et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001, 78(4):842-853.
37. Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49(1):15-23.
38. Guillemin G.J., Wang L., Brew B.J. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2005, 2:16.
39. Heyes M.P., Lackner A. Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia. J Neurochem 1990, 55(1):338-341.
40. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115(Pt 5):1249-1273.
41. Heyes M.P., Saito K., Major E.O., Milstien S., Markey S.P., Vickers J.H. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993, 116(Pt 6):1425-1450.
42. Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., Markey S.P. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 1996, 320(Pt 2):595-597.
43. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21(19):7463-7473.
44. Hoes M.J. The clinical significance of an elevated excretion of xanthurenic acid in psychiatric patients. Acta Psychiatr Belg 1979, 79(6):638-646.
45. Irwin M., Smith T.L., Gillin J.C. Low natural killer cytotoxicity in major depression. Life Sci 1987, 41(18):2127-2133.
46. Issa F., Gerhardt G.A., Bartko J.J., Suddath R.L., Lynch M., Gamache P.H., et al. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses. Psychiatry Res 1994, 52(3):237-249.
47. Jospeh M.H., Baker H.F., Crow T.J., Riley G.J., Risby D. Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites of the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology (Berl) 1979, 62(3):279-285.
48. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000, 48(7):627-640.
49. Kent S., Bluthe R.M., Kelley K.W., Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992, 13(1):24-28.
50. Kim J.P., Choi D.W. Quinolinate neurotoxicity in cortical cell culture. Neuroscience 1987, 23(2):423-432.
51. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20(3):379-382.
52. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007, 104(1-3):91-95.
53. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59(2):123-129.
54. Knox W.E. Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: specific enzyme adaptation and stimulation of the pituitary adrenal system. Br J Exp Pathol 1951, 32(5):462-469.
55. Kohl C., Walch T., Huber R., Kemmler G., Neurauter G., Fuchs D., et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord 2005, 86(2-3):135-142.
56. Krause D., Suh H.S., Tarassishin L., Cui Q.L., Durafourt B.A., Choi N., et al. The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. Am J Pathol 2011, 179(3):1360-1372.
57. Lapin I.P., Oxenkrug G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969, 1(7586):132-136.
58. Leklem J.E. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr 1971, 24(6):659-672.
59. Mackay G.M., Forrest C.M., Christofides J., Bridel M.A., Mitchell S., Cowlard R., et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol 2009, 36(4):425-435.
60. Maes M., De Ruyter M., Suy E. Xanthurenic acid flow in 24-hour urine following L-tryptophan loading in depressive patients. Acta Psychiatr Belg 1986, 86(2):120-130.
61. Maes M., De Ruyter M., Hobin P., Suy E. Relationship between the dexamethasone suppression test and the L-tryptophan/competing amino acids ratio in depression. Psychiatry Res 1987, 21(4):323-335.
62. Maes M., Bosmans E., Suy E., Minner B., Raus J. Impaired lymphocyte stimulation by mitogens in severely depressed patients. A complex interface with HPA-axis hyperfunction, noradrenergic activity and the ageing process. Br J Psychiatry 1989, 155:793-798.
63. Maes M., Stevens W., DeClerck L., Bridts C., Peeters D., Schotte C., et al. Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. Acta Psychiatr Scand 1992, 86(6):423-431.
64. Maes M., Meltzer H.Y., Scharpe S., Bosmans E., Suy E., De Meester I., et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993, 49(2):151-165.
65. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995, 20(2):111-116.
66. Maes M., Lin A.H., Ombelet W., Stevens K., Kenis G., De Jongh R., et al. Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms. Psychoneuroendocrinology 2000, 25(2):121-137.
67. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 2001, 6(4):475-480.
68. Maes M., Verkerk R., Bonaccorso S., Ombelet W., Bosmans E., Scharpe S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002, 71(16):1837-1848.
69. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 2009, 30(6):715-722.
70. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):702-721.
71. Mangoni A. The "kynurenine shunt" and depression. Adv Biochem Psychopharmacol 1974, 11:293-298.
72. Mannaioni G., Carpenedo R., Moroni F. 5-hydroxyindole causes convulsions and increases transmitter release in the CA1 region of the rat hippocampus. Br J Pharmacol 2003, 138(1):245-253.
73. Manuelpillai U., Ligam P., Smythe G., Wallace E.M., Hirst J., Walker D.W. Identification of kynurenine pathway enzyme mRNAs and metabolites in human placenta: up-regulation by inflammatory stimuli and with clinical infection. Am J Obstet Gynecol 2005, 192(1):280-288.
74. McAdams C., Leonard B.E. Neutrophil and monocyte phagocytosis in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17(6):971-984.
75. Melillo G., Cox G.W., Radzioch D., Varesio L. Picolinic acid, a catabolite of L-tryptophan, is a costimulus for the induction of reactive nitrogen intermediate production in murine macrophages. J Immunol 1993, 150(9):4031-4040.
76. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today 1999, 20(10):469-473.
77. Miller C.L., Llenos I.C., Dulay J.R., Barillo M.M., Yolken R.H., Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004, 15(3):618-629.
78. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006, 1073-1074:25-37.
79. Moffett J.R., Namboodiri M.A. Tryptophan and the immune response. Immunol Cell Biol 2003, 81(4):247-265.
80. Moffett J.R., Blinder K.L., Venkateshan C.N., Namboodiri M.A. Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs. Cell Tissue Res 1998, 293(3):525-534.
81. Moller S.E. Tryptophan to competing amino acid ratio in depressive disorder: relation to efficacy of antidepressive treatments. Acta Psychiatr Scand Suppl 1985, 325:3-31.
82. Moller S.E., Amdisen A. Plasma neutral amino acids in mania and depression: variation during acute and prolonged treatment with L-tryptophan. Biol Psychiatry 1979, 14(1):131-139.
83. Musso T., Gusella G.L., Brooks A., Longo D.L., Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 1994, 83(5):1408-1411.
84. Myint A.M. Kynurenines: from the perspective of major psychiatric disorders. FEBS J 2012, 279(8):1375-1385.
85. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003, 61(5-6):519-525.
86. Myint A.M., Kim Y.K., Verkerk R., Park S.H., Scharpe S., Steinbusch H.W., et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord 2007, 102(1-3):65-72.
87. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007, 98(1-2):143-151.
88. Myint Aye Mu, Schwarz Markus J. Interaction Between Inflammatory State and Neurochemical Changes in Major Psychiatric Disorders. Psychiatric Disorders - Worldwide Advances 2011, ISBN: 978-953-307-833-5, InTech. T. Uehara (Ed.).
89. Myint A.M., Schwarz M.J., Verkerk R., Mueller H.H., Zach J., Scharpe S., et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 2011, 25:1576-1581.
90. Myint A.M., Bondy B., Baghai T.C., Eser D., Nothdurfter C., Schule C., et al. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav Immun 2013, 31:128-133.
91. Nakamura T., Niimi S., Nawa K., Noda C., Ichihara A., Takagi Y., et al. Multihormonal regulation of transcription of the tryptophan 2,3-dioxygenase gene in primary cultures of adult rat hepatocytes with special reference to the presence of a transcriptional protein mediating the action of glucocorticoids. J Biol Chem 1987, 262(2):727-733.
92. Nishino S., Ueno R., Ohishi K., Sakai T., Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression. Am J Psychiatry 1989, 146(3):365-368.
93. Oades R.D., Dauvermann M.R., Schimmelmann B.G., Schwarz M.J., Myint A.M. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism-effects of medication. Behav Brain Funct 2010, 6:29.
94. Oades R.D., Myint A.M., Dauvermann M.R., Schimmelmann B.G., Schwarz M.J. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav Brain Funct 2010, 6:32.
95. O'Connor J.C., Andre C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009, 29(13):4200-4209.
96. O'Connor J.C., Lawson M.A., Andre C., Briley E.M., Szegedi S.S., Lestage J., et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009, 182(5):3202-3212.
97. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14(5):511-522.
98. Okuda S., Nishiyama N., Saito H., Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 1998, 70(1):299-307.
99. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254(5037):1515-1518.
100. Perez-De La Cruz V., Carrillo-Mora P., Santamaria A. Quinolinic Acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 2012, 5:1-8.
101. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982, 247(1):184-187.
102. Pertz H., Back W. Synthesis and resolution of chiral ring-opened serotonin analogs of the 5-hydroxykynuramine type. Pharm Acta Helv 1988, 63(4-5):128-131.
103. Pocivavsek A., Wu H.Q., Elmer G.I., Bruno J.P., Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci 2012, 35(10):1605-1612.
104. Puccetti P., Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007, 7(10):817-823.
105. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010, 15(4):393-403.
106. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45(9):1085-1098.
107. Raju T.N. The Nobel chronicles. 1927: Julius Wagner-Jauregg (1857-1940). Lancet 1998, 352(9141):1714.
108. Ren S., Correia M.A. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase?. Arch Biochem Biophys 2000, 377(1):195-203.
109. Rosenberg D.R., Macmaster F.P., Mirza Y., Smith J.M., Easter P.C., Banerjee S.P., et al. Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 2005, 58(9):700-704.
110. Rozov S.V., Filatova E.V., Orlov A.A., Volkova A.V., Zhloba A.R., Blashko E.L., et al. N1-acetyl-N2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res 2003, 35(4):245-250.
111. Sakakeeny L., Roubenoff R., Obin M., Fontes J.D., Benjamin E.J., Bujanover Y., et al. Plasma pyridoxal-5-phosphate is inversely associated with systemic markers of inflammation in a population of u.s. Adults. J Nutr 2012, 142(7):1280-1285.
112. Salter M., Pogson C.I. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J 1985, 229(2):499-504.
113. Santoso D.I., Rogers P., Wallace E.M., Manuelpillai U., Walker D., Subakir S.B. Localization of indoleamine 2,3-dioxygenase and 4-hydroxynonenal in normal and pre-eclamptic placentae. Placenta 2002, 23(5):373-379.
114. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219(4582):316-318.
115. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001, 50(7):521-530.
116. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001, 56(4):483-486.
117. Seabrook T.J., Jiang L., Maier M., Lemere C.A. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006, 53(7):776-782.
118. Selye H. Interactions between systemic and local stress. Br Med J 1954, 1(4872):1167-1170.
119. Shepard P.D., Joy B., Clerkin L., Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003, 28(8):1454-1462.
120. Silvestre J.S., Nadal R., Pallares M., Ferre N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety 1997, 5(1):29-33.
121. Smith R.S. The macrophage theory of depression. Med Hypotheses 1991, 35(4):298-306.
122. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995, 45(2):135-141.
123. Song C., Dinan T., Leonard B.E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 1994, 30(4):283-288.
124. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998, 49(3):211-219.
125. Sperner-Unterweger B., Whitworth A., Kemmler G., Hilbe W., Thaler J., Weiss G., et al. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr Res 1999, 38(1):61-70.
126. Steiner J., Walter M., Gos T., Guillemin G.J., Bernstein H.G., Sarnyai Z., et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J Neuroinflammation 2011, 8:94.
127. Stelzer A., Shi H. Impairment of GABAA receptor function by N-methyl-D-aspartate-mediated calcium influx in isolated CA1 pyramidal cells. Neuroscience 1994, 62(3):813-828.
128. Takahashi T., Wood S.J., Soulsby B., McGorry P.D., Tanino R., Suzuki M., et al. Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophr Res 2009, 108(1-3):49-56.
129. Walker D.W., Curtis B., Lacey B., Nitsos I. Kynurenic acid in brain and cerebrospinal fluid of fetal, newborn, and adult sheep and effects of placental embolization. Pediatr Res 1999, 45(6):820-826.
130. Watanabe Y., Fujiwara M., Yoshida R., Hayaishi O. Stereospecificity of hepatic L-tryptophan 2,3-dioxygenase. Biochem J 1980, 189(3):393-405.
131. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005, 10(6):538-544.
132. Wood K., Harwood J., Coppen A. The effect of antidepressant drugs on plasma kynurenine in depressed patients. Psychopharmacology (Berl) 1978, 59(3):263-266.
133. Wu H.Q., Rassoulpour A., Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?. J Neural Transm 2007, 114(1):33-41.
134. Yao J.K., Dougherty G.G., Reddy R.D., Keshavan M.S., Montrose D.M., Matson W.R., Rozen S., Krishnan R.R., McEvoy J., Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2010, 15(9):938-953.
135. Yasui H., Takai K., Yoshida R., Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci U S A 1986, 83(17):6622-6626.
136. Yuwiler A., Oldendorf W.H., Geller E., Braun L. Effect of albumin binding and amino acid competition on tryptophan uptake into brain. J Neurochem 1977, 28(5):1015-1023.
137. Zwart R., De Filippi G., Broad L.M., McPhie G.I., Pearson K.H., Baldwinson T., et al. 5-Hydroxyindole potentiates human alpha 7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 2002, 43(3):374-384.